The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

The aim of the present study is to investigate the effects of canagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, on non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC) in a mouse model of diabetes and NASH-HCC. First, mice aged five weeks w...

Descripción completa

Detalles Bibliográficos
Autores principales: Jojima, Teruo, Wakamatsu, Sho, Kase, Masato, Iijima, Toshie, Maejima, Yuko, Shimomura, Kenju, Kogai, Takahiko, Tomaru, Takuya, Usui, Isao, Aso, Yoshimasa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829338/
https://www.ncbi.nlm.nih.gov/pubmed/31652578
http://dx.doi.org/10.3390/ijms20205237

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6829338/
https://www.ncbi.nlm.nih.gov/pubmed/31652578
http://dx.doi.org/10.3390/ijms20205237

Ejemplares similares